Skip to main content
Premium Trial:

Request an Annual Quote

Interleukin Genetics' Q2 Revenues Rise 33 Percent

NEW YORK (GenomeWeb News) – Interleukin Genetics today reported that its second-quarter revenues rose 33 percent on higher genetic test sales.

The Waltham, Mass.-based firm brought in total revenues of $800,000 for the three months ended June 30, compared to $600,000 for the second quarter of 2010. Almost all of its revenues were from genetic test sales.

Interleukin Genetics CEO Lewis Bender said that the revenue growth was "primarily driven by partnerships for our Weight Management Genetic Test."

The firm's net loss declined to $1.2 million, or $.03 per share, from $1.4 million, or $.04 per share, for Q2 2010.

Its R&D spending climbed around 11 percent to $359,799 from $325,298, while its SG&A expenses fell 19 percent to $1.3 million from $1.6 million. Interleukin said the drop was due to "lower compensation, professional fees, and promotion expenses partially offset by increased patent-related legal fees and sales commissions paid to Amway."

Interleukin Genetics finished the quarter with $1.7 million in cash and cash equivalents.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.